Shanghai Rightongene Financials
| 688217 Stock | 20.84 0.26 1.23% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 334.7 K | 352.3 K |
|
|
Shanghai | Select Account or Indicator |
Understanding current and past Shanghai Rightongene Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Shanghai Rightongene's financial statements are interrelated, with each one affecting the others. For example, an increase in Shanghai Rightongene's assets may result in an increase in income on the income statement.
Please note, the presentation of Shanghai Rightongene's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Shanghai Rightongene's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Shanghai Rightongene's management manipulating its earnings.
Shanghai Rightongene Stock Summary
Shanghai Rightongene competes with Industrial, China Construction, Agricultural Bank, Bank of China, and PetroChina. Shanghai Rightongene is entity of China. It is traded as Stock on SHG exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | China Stock View All |
| Exchange | Shanghai Stock Exchange |
| Business Address | No 147, Lane |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.rightongene.com |
| Phone | 86 21 3328 2601 |
You should never invest in Shanghai Rightongene without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Shanghai Stock, because this is throwing your money away. Analyzing the key information contained in Shanghai Rightongene's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Shanghai Rightongene Key Financial Ratios
Shanghai Rightongene's financial ratios allow both analysts and investors to convert raw data from Shanghai Rightongene's financial statements into concise, actionable information that can be used to evaluate the performance of Shanghai Rightongene over time and compare it to other companies across industries.| Revenue | 258.21 M | ||||
| Gross Profit | 257.7 M | ||||
| EBITDA | 25.94 M | ||||
| Net Income | 7.93 M | ||||
| Total Asset | 1.04 B |
Shanghai Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Shanghai Rightongene's current stock value. Our valuation model uses many indicators to compare Shanghai Rightongene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Shanghai Rightongene competition to find correlations between indicators driving Shanghai Rightongene's intrinsic value. More Info.Shanghai Rightongene Biotechnology is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Shanghai Rightongene by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Shanghai Rightongene's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Shanghai Rightongene Systematic Risk
Shanghai Rightongene's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Shanghai Rightongene volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Shanghai Rightongene correlated with the market. If Beta is less than 0 Shanghai Rightongene generally moves in the opposite direction as compared to the market. If Shanghai Rightongene Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Shanghai Rightongene is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Shanghai Rightongene is generally in the same direction as the market. If Beta > 1 Shanghai Rightongene moves generally in the same direction as, but more than the movement of the benchmark.
Shanghai Rightongene Biotechnology Total Assets Over Time
Shanghai Rightongene Thematic Clasifications
Shanghai Rightongene Biotechnology is part of Biotech investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services
This theme covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services. Get More Thematic Ideas
| Biotech | View |
Shanghai Rightongene November 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Shanghai Rightongene help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Shanghai Rightongene Biotechnology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Shanghai Rightongene Biotechnology based on widely used predictive technical indicators. In general, we focus on analyzing Shanghai Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Shanghai Rightongene's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.06 | |||
| Information Ratio | 0.1008 | |||
| Maximum Drawdown | 26.39 | |||
| Value At Risk | (5.70) | |||
| Potential Upside | 6.97 |
Complementary Tools for Shanghai Stock analysis
When running Shanghai Rightongene's price analysis, check to measure Shanghai Rightongene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Shanghai Rightongene is operating at the current time. Most of Shanghai Rightongene's value examination focuses on studying past and present price action to predict the probability of Shanghai Rightongene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Shanghai Rightongene's price. Additionally, you may evaluate how the addition of Shanghai Rightongene to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |